Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,181.2
-58.8 (-1.81%)

 

  • STI Straits Times Index
    3,181.2
    -58.8 (-1.81%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,551.6
    -21.2 (-1.35%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    27,940.5
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,976.5
    -84.2 (-2.75%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,215.7
    -127.8 (-0.55%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,111.2
    -22.0 (-0.36%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,176.7
    -69.4 (-3.09%)
    Index delayed 20 minutes
  • XAO XAO
    7,098.4
    -104.8 (-1.45%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 2,422.8M
  • Value: 2,070.9M
  • Rise: 59
  • Fall: 358
  • Unch: 399

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Medtecs Intl0.172+0.068
CWX Global0.004-
Healthway Med0.046+0.007
Genting Sing0.875-0.035
AsiaMedic0.017+0.002
Singtel3.360-0.030
Rex Intl0.168-0.013
AusGroup^0.037-0.005
YZJ Shipbldg SGD0.985-0.055
Spackman0.017-0.001

World Indices

World Indices
Name Last Change
Nasdaq 9,139.3 -175.6
HSI 27,940.5
HSCEI 10,969.3
Jakarta 6,111.2
Nikkei 225 23,215.7
SSE Comp 2,976.5 -84.2
Shanghai A 3,118.9 -88.2
Shanghai B 248.6 -8.9
PSE Comp 0.0
KOSPI 2,176.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

STEMLINE THERAPEUTICS INC STEMLINE THERAPEUTICS
Updated on 27 Jan 2020 (End of trading day)
Last (USD): 6.460 Change: -0.300 High: 6.840 Remarks: -
Change (%): -4.44 Low: 6.450
Open 6.600 Yesterday's Close 6.76
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 953,697 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -1.69611 Trailing EPS (USD) e -1.71103 NAV (USD) b 3.4997
PE a - Trailing PE f - Price / NAV b 1.8459
Dividend (USD) d - Cash In Hand (USD) g 0.5462 Issued & Paid-up Shares c 50,129,000
Dividend Yield (%) d - Price / Cash In Hand g 11.827 Treasury Shares h -
Beta - 75 Daysi 1.473 R-Squared - 75 Days(%)i 5.61 Market Cap (M) 323.833
Beta - 500 Daysi -0.100 R-Squared - 500 Days (%)i 0.09 Enterprise Value (M) 150.642
Piotroski F Score 2 Exchange Code STML Par Value ( $ ) n.a.
52 Weeks Volatility (%) 65.93 Free Float (%) 92.4
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 13 Nov 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference STEMLINE THERAPEUTICS INC NASDAQ 323.833 - - 1.8459 -
Industry Biotechnology NASDAQ 2,320.557 357.556 92.382 5.7714 0.764
Local Peer AMGEN INC NASDAQ 132,473.323 15.782 16.422 12.1235 2.509
Local Peer GILEAD SCIENCES INC NASDAQ 80,754.524 14.804 29.987 3.9194 3.620
Local Peer VERTEX PHARMACEUTICAL NASDAQ 58,468.196 27.890 27.274 11.1296 -
Local Peer BIOGEN INC NASDAQ 50,729.464 11.450 9.402 3.6246 -
Local Peer ILLUMINA INC NASDAQ 46,146.240 55.867 47.427 10.3956 -
Local Peer REGENERON PHARMACEUTICALS INC NASDAQ 37,266.948 15.246 17.380 3.5477 -
Local Peer ALEXION PHARMACEUTICAL INC NASDAQ 23,301.942 300.282 15.848 2.2477 -
Local Peer SEATTLE GENETICS INC NASDAQ 18,926.156 - - 10.6350 -
Local Peer INCYTE CORPORATION NASDAQ 16,385.250 149.647 40.461 6.7637 -
Local Peer BIOMARIN PHARMACEUTICAL NASDAQ 15,199.868 - - 4.9440 -
Local Peer GALAPAGOS NV SPON ADR REPR 1 ORD SHS NASDAQ 14,696.869 - 47.354 5.3173 -
Local Peer ALNYLAM PHARMACEUTICALS INC NASDAQ 13,047.675 - - 8.1189 -
Other Local Peers EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), 10X GENOMICS INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), MODERNA INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), EXELIXIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), FIBROGEN INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), NATERA INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ALKERMES PLC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), VIELA BIO INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), EPIZYME INC (NASDAQ), XENCOR INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ALECTOR INC (NASDAQ), INSMED INC (NASDAQ), REGENXBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), NEXTCURE INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), DERMIRA INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), XBIOTECH INC (NASDAQ), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), INTREXON CORP (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), OMEROS CORP (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), RETROPHIN INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ARDELYX INC (NASDAQ), AVROBIO INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), AGENUS INC (NASDAQ), MACROGENICS INC (NASDAQ), MERUS B V (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), COMPUGEN (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), CABALETTA BIO INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), ANAPTYSBIO INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), RECRO PHARMA INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), PERSONALIS INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), NEUROINSIGHTS NEUROTECH (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), NOVAVAX INC (NASDAQ), GERON CORP (NASDAQ), MEDICINOVA INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), KAMADA (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), ATHERSYS INC (NASDAQ), IMV INC (NASDAQ), AFFIMED N V (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), XOMA CORP (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), CHIASMA INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ARAVIVE INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), CONTRAFECT CORP (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), VERASTEM INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), SAVARA INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), VACCINEX INC (NASDAQ), CHIMERIX INC (NASDAQ), ADURO BIOTECH INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), OTONOMY INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), ORGENESIS INC (NASDAQ), SESEN BIO INC (NASDAQ), EQUILLIUM INC (NASDAQ), TREVENA INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), SYNLOGIC INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), VERMILLION INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), SOLIGENIX INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), CURIS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), INMUNE BIO INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), ADVAXIS INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), ZAFGEN INC (NASDAQ), EVOGENE LTD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), OCUGEN INC (NASDAQ), VAXART INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), UNUM THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), SOPHIRIS BIO INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), ATYR PHARMA INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), BIO-PATH HOLDINGS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), TROVAGENE INC (NASDAQ), PRECIPIO INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), TOCAGEN INC (NASDAQ), BIOCEPT INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), SENESTECH INC (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), OPGEN INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ)
Global Peer CSL ASX 141,910.746 52.894 52.894 18.9640 0.849
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer AGILENT TECHNOLOGIES INC NYSE 26,849.440 84.967 25.070 5.6549 0.706
Global Peer SINO BIOPHARM HKEx 143,847.408 13.425 13.933 4.2839 0.640
Global Peer WUXI BIO HKEx 134,349.414 179.875 140.620 13.8295 -
Global Peer BEIGENE HKEx 100,670.850 - - 10.0445 -
Global Peer Lonza SGX 5,937.453 6.613 6.613 0.6568 4.787
Global Peer GENSCRIPT BIO HKEx 33,091.696 199.005 - 9.3319 -
Global Peer 3SBIO HKEx 27,939.670 18.469 22.480 2.7538 -
Global Peer EMERGENT BIOSOLUTIONS INC NYSE 2,763.949 44.082 642.779 2.6705 -
Other Global Peers ALPHAMAB-B (HKEx), HAOHAI BIOTEC (HKEx), POLYNOVO LIMITED (ASX), MYOVANT SCIENCES LTD (NYSE), MESOBLAST LTD (ASX), FRONTAGE (HKEx), CKLIFE SCIENCES (HKEx), NANOVIRICIDES INC (NYSE American), AVITA MEDICAL LTD (ASX), VIVA BIOTECH (HKEx), ASCENTAGE-B (HKEx), KADMON HLDGS INC (NYSE), SINOMAB BIO-B (HKEx), ARCUS BIOSCIENCES INC (NYSE), ASCLETIS-B (HKEx), ESSEX BIO-TECH (HKEx), LEE'S PHARM (HKEx), DPHARMA (Bursa), NEXT SCIENCE LTD (ASX), PFENEX INC (NYSE American), TELIX PHARMACEUTIC (ASX), BBI LIFE SCI (HKEx), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), NEUREN PHARMACEUTICALS LTD (ASX), LINEAGE CELL THERAPEUTICS INC (NYSE American), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), UNI-BIO GROUP (HKEx), RESAPP HEALTH LIMITED (ASX), CEL-SCI CORP (NYSE American), PYC THERAPEUTICS LIMITED (ASX), ENZO BIOCHEM INC (NYSE), 22ND CENTURY GROUP INC (NYSE American), PALATIN TECHNOLOGIES INC (NYSE American), IMUGENE LIMITED (ASX), CYNATA THERAPEUTICS LTD (ASX), IMMUTEP LTD (ASX), ONCOSIL MEDICAL LIMITED (ASX), SYNTHETIC BIOLOGICS INC (NYSE American), ORTHOCELL LIMITED (ASX), CT ENTERPRISE (HKEx), ISORAY INC (NYSE American), INVEX THERAPEUTICS LTD NPV (ASX), BIOSINO BIO-TEC (HKEx), BIOTRON (ASX), GENETIC TECHNOLOGIES (ASX), KAZIA THERAPEUTICS LIMITED (ASX), ACTINOGEN MEDICAL LTD (ASX), ARMATA PHARMACEUTICALS INC (NYSE American), REGENT PACIFIC (HKEx), ANTEOTECH LIMITED (ASX), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), TALI DIGITAL LIMITED (ASX), IBIO INC (NYSE American), EXTRAWELL PHAR (HKEx), CCP TECHNOLOGIES LTD (ASX), ORAGENICS INC (NYSE American), RHINOMED LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), PROTEOMICS INTL LABORATORIES LTD (ASX), IMMURON LIMITED (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), CELLMID LIMITED (ASX), PATRYS LIMITED (ASX), Suntar Eco-City^ (SGX), CONTANGO ASSET MANAGEMENT LIMITED (ASX), REGENEUS LTD (ASX), ADALTA LTD (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), HOLISTA COLLTECH LIMITED (ASX), ANATARA LIFESCIENCES LTD (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), AIM IMMUNOTECH INC (NYSE American), LIVING CELL TECHNOLOGIES (ASX), HAO WEN HLDGS (HKEx), BENITEC BIOPHARMA LTD (ASX), AUSTRALIAN PRIMARY HEMP LTD (ASX), BIOXYNE LIMITED (ASX), MEDIBIO LIMITED (ASX), QT Vascular (SGX), MGRC (Bursa), TBG DIAGNOSTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.455
-6.58 %
10 Days --0.110
-1.67 %
20 Days --4.170
-39.23 %
Medium Term Return 3 Months --3.480
-35.01 %
6 Months --7.250
-52.88 %
1 Year --4.240
-39.63 %
Long Term Return 2 Years --9.990
-60.73 %
3 Years --3.740
-36.67 %
5 Years --7.940
-55.14 %
Annualised Return Annualised --
-14.81 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 6.010 - 18.220 Change From 1 Year Low +0.450 % Change From 1 Year Low (%) +7.49
Change From 1 Year High -11.760 % Change From 1 Year High (%) -64.54
2 Years Range 6.010 - 20.550 Change From 2 Years Low +0.450 % Change From 2 Years Low (%) +7.49
Change From 2 Years High -14.090 % Change From 2 Years High (%) -68.56
5 Years Range 3.880 - 20.550 Change From 5 Years Low +2.580 % Change From 5 Years Low (%) +66.49
Change From 5 Years High -14.090 % Change From 5 Years High (%) -68.56
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Historical Price Data

Date Open High Low Close Volume VWAP
27 Jan 2020 6.600 6.840 6.450 6.460 953,697 -
24 Jan 2020 6.940 7.150 6.720 6.760 1,141,579 -
23 Jan 2020 6.930 7.000 6.660 6.930 879,499 -
22 Jan 2020 6.990 7.140 6.820 6.960 1,025,008 -
21 Jan 2020 7.030 7.170 6.620 6.915 1,608,605 -
17 Jan 2020 7.140 7.390 6.940 7.030 1,317,993 -
16 Jan 2020 6.940 7.470 6.820 7.030 2,426,197 -
15 Jan 2020 6.720 6.900 6.505 6.840 2,689,895 -
14 Jan 2020 7.260 7.260 6.010 6.570 9,818,490 -
13 Jan 2020 9.780 9.780 8.520 9.430 710,150 -
10 Jan 2020 10.280 10.304 9.780 9.810 517,452 -
09 Jan 2020 10.480 10.540 10.200 10.250 238,696 -
08 Jan 2020 10.550 10.580 10.270 10.430 399,583 -
07 Jan 2020 10.710 10.870 10.450 10.550 371,316 -
06 Jan 2020 10.660 10.850 10.270 10.735 318,169 -
03 Jan 2020 10.700 10.900 10.600 10.785 419,704 -
02 Jan 2020 10.930 10.930 10.460 10.790 422,904 -
31 Dec 2019 10.420 10.730 10.230 10.630 370,088 -
30 Dec 2019 10.480 10.690 10.120 10.460 454,084 -
27 Dec 2019 10.800 10.817 10.310 10.400 351,725 -
26 Dec 2019 11.100 11.250 10.510 10.650 443,462 -
24 Dec 2019 11.190 11.384 10.780 11.080 389,804 -
Summary
Current 2 Weeks
(13 Jan 2020 to 27 Jan 2020)
9.780 9.780 6.010 6.460 22,571,113 -
Previous 2 Weeks
(27 Dec 2019 to 10 Jan 2020)
10.800 10.817 6.010 9.810 3,863,721 -
4 Weeks from
(27 Nov 2019 to 26 Dec 2019)
10.500 10.610 6.010 10.650 8,869,183 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.